MA
Maze Therapeutics, Inc.
MAZE · NASDAQ
$22.52 -3.84% (-$0.90)
1M -23.92%
Market Cap $1.25B
P/E Ratio -
Div. Yield -
ROE 34.94%
Piotroski F-Score Weak
3/9Valuation
36 /100
Fair P/B 2.75x
P/S 62.32x
PEG N/A
Growth
100 /100
Growing Book val. growth 51.82%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak FCF margin 534.20%
Op. margin 728.06%
Gross margin 95.29%
Quality
0 /100
Poor Asset turnover 0.04x
ROA 25.13%
ROIC 28.35%
Debt
69 /100
Low Current ratio 18.31x
Int. coverage -73.34x
Debt/Equity 0.13x
Stability
1 /100
Unstable EPS volatility 2,355.06%
Profitable years 0
Beta 2.16x
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre MAZE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jason Coloma
Employees
141
Headquarters
South San Francisco
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report